Purpose: Second malignancies in patients with pure testicular seminoma were studied in order to look for adverse late effects of treatment and to study the significance of second malignancies during follow-up. Patients, Methods: In a multicentric investigation, 839 consecutive patients with pure testicular seminoma were observed for a median follow-up of 3.9 years. Thirty-seven patients had been excluded from the study because they already had had either a contralateral testicular germ cell tumor or another malignancy. 758 patients received radiotherapy, 76 underwent chemotherapy, 5 had surveillance only. The expected rate of second cancers was calculated according to the data of the cancer registry of Saarland, Germany. Results: Twenty-two second cancers (13 contralateral testicular tumors, 9 extratesticular malignancies) were recorded. The overall risk of having a second cancer was RR = 4.8 (95% CI 3.0–7.3). The risk of having a subsequent testicular tumor is RR = 44.8 (95% Cl 23.9–76.7). 1.1% of the patients developed a nontesticular second tumor. The risk of having a nontesticular second cancer is RR = 2.1 (95% CI 1.0–4.0). A significantly increased risk was observed for renal cell cancer as well (RR = 12.5; 95% Cl: 1.5–45.1). Increased RR without reaching statistical significance were found for rectal cancer (RR = 5.0; 95% Cl: 0.1–27.9) and non-Hodgkin lymphoma (RR = 6.7; 95% CI 0.2–37.1). None of the second cancers were directly located within the radiation field; 5 neoplasms arose at the border of the radiation field. Conclusions: This study confirmed the increased risk of having a second testicular germ cell cancer. There is also a small but definitely increased overall risk of having a nontesticular second cancer. Treatment-unrelated factors – possibly genetic predisposition – must be considered for a substantial number of these second tumors, since in the present study the follow-up was rather short and most of the second cancers were located outside of the radiation fields. In particular, the association of renal cancer with testicular cancer appears to be a more than chance occurrence. Second cancer is a real hazard following treatment of testicular cancers and should always be considered during follow-up.

Keywords:
Testicular seminoma, Radiotherapy, Chemotherapy, Multiple neoplasms, Renal cell cancer
1.
Albers P: Diagnostik und Therapie von Hodentumoren. Urologe A 1997;36:387–396.
2.
Horwich A, Dearnaley DP: Treatment of seminoma. Semin Oncol 1992;19:171–180.
3.
Weissbach L, Bussar-Maatz R: Pathogenese, Diagnostik und Therapie von Hodentumoren. Urologe A 1996;35:163–172.
4.
Hay JH, Duncan W, Kerr GR: Subsequent malignancies in patients irradiated for testicular tumours. Br J Radiol 1984;57:597–602.
5.
Bokemeyer C, Schmoll HJ: Treatment of testicular cancer and the development of secondary malignancies. J Clin Oncol 1995;13:283–292.
6.
Travis LB, Curtis RE, Storm H, Hall P, Holowaty E, Van Leeuwen FE, Kohler BA, Pukkala E, Lynch CF, Andersson M, Bergfeldt K, Clarke EA, Wiklund T, Stoter G, Gospodarowicz M, Sturgeon J, Fraumeni JF, Boice JD Jr: Risk of second malignat neoplasms among long-term survivors of testicular cancer. J Natl Cancer Inst 1997;89:1429–1439.
7.
Warren S, Gates O: Multiple primary malignant tumors – a survey of the literature and statistical study. Am J Cancer 1932;16:1358–1414.
8.
Moertel CG: Multiple primary malignant neoplasms. Historical perspectives. Cancer 1977;40:1786–1792.
9.
Weissbach L, Bussar-Maatz R: HCG-positive seminoma. Eur Urol 1993;23 (suppl 2):29–32.
10.
Hartmann M, Pottek T, Bussar-Maatz R, Weissbach L: Elevated human chorionic gonadotropin concentrations in the testicular vein and in peripheral venous blood in seminoma patients. An analysis of various parameters. Eur Urol 1997;31:408–413.
11.
Peckham M: Testicular cancer. Acta Oncol 1988;7:439–453.
12.
Weissbach L, Boedefeld EA, Seeber S: Hodentumoren: Frühzeitige Diagnose und stadiengerechte Therapie sichern den Erfolg. Dtsch Ärztebl 1985;82:1340–1349.
13.
Hainsworth JD, Greco FA: Testicular germ cell neoplasms. Am J Med 1983;75:817–832.
14.
Krebsregister Saarland, Saarland in Zahlen: Morbidität an bösartigen Neubildungen im Saarland. Saarbrücken: Saarland, 1989–1994.
15.
Breslow NE, Day NE: Statistical methods in cancer research. The design and analysis of cohort studies. IARC Sci Publ 1987; 82 (2).
16.
Dieckmann KP, Boeckmann W, Brosig W, Jonas D, Bauer HW: Bilateral testicular germ cell tumours. Report of nine cases and review of the literature. Cancer 1986;57:1254–1258.
17.
Bokemeyer C, Schmoll HJ, Schöffski P, Harstrick A, Bading M, Poliwoda H: Bilateral testicular tumours: Prevalence and clinical implications. Eur. J. Cancer 1993;29A:874–876.
18.
Osterlind A, Berthelsen JG, Abildgaard N, et al: Risk of bilateral testicular germ cell cancer in Denmark:1960–1984. J Natl Cancer Inst 1991;83:1391–1395.
19.
Hoff Wanderas E, Fossa SD, Tretli S: Risk of a second germ cell cancer after treatment of a primary germ cell cancer in 2201 Norwegian male patients. Eur J Cancer 1997;33:244–252.
20.
van Leeuwen FE, Stiggelbout AM, Belt-Dousebout AWvd, et al: Second cancer risk following testicular cancer: A follow-up study of 1,909 patients. J Clin Oncol 1993;11:415–424.
21.
Philipsen JP, Gimbel HM: Cancer of the testis in an 80 year old man with a former contralateral testicular cancer (in Danish). Ugeskr Laeger 1994;156:2908–2909.
22.
Rajpert-De Meyts E, Skakkebaek NE: The possible role of sex hormones in the development of testicular cancer. Eur Urol 1993;23:54–61.
23.
Nicholson PW, Harland SJ: Inheritance and testicular cancer. Br J Cancer 1995;71:421–426.
24.
Weissbach L, Bamberg M, Schmoll H-J: Interdisziplinäre Konsensuskonferenz zur ‘Diagnostik und Therapie von Hodentumoren’. Urologe A 1997;36:362–368.
25.
Skakkebaek NE, Berthelsen JG, Giwercman A, Müller J: Carcinoma in situ of the testis: Possible origin from gonocytes and precursor of all types of germ cell tumours except spermatocytoma. Int J Androl 1987;10:19–28.
26.
Dieckmann K-P, Loy V: The value of the biopsy of the contralateral testis in patients with germ cell cancer: The recent German experience. APMIS 1998;106:13–20.
27.
Dieckmann KP, Wegner HEH, Krain J: Multiple primary neoplasms in patients with testicular germ cell tumor. Oncology 1994;51:450–458.
28.
Culp DA, Graf RA, Haschek H: Testicular tumor. J Urol 1963;89:843–850.
29.
Lynch DF, Herr HW: Radiation-induced sarcoma following radiotherapy for testicular tumor. J Urol 1981;126:845–846.
30.
Ehrengut W, Schwartau M, Hubmann R: Testikuläre Vorerkrankungen bei Patienten mit Hodentumoren unter besonderer Berücksichtigung der Mumpsorchitis. Urologe A 1980;19:283–288.
31.
MacKay EN, Sellers AH: A statistical study of malignant testicular tumours based on the experience of the Ontario Cancer Foundation Clinics, 1938–1951. Can Med Assoc J 1966;94:889–899.
32.
Nefzger MD, Mostofi FK: Survival after surgery for germinal malignancies of the testis. Effects of surgery and radiation therapy. Cancer 1972;30:1233–1240.
33.
Zak Bl, Fomin NS: Primary multiple tumours of the genito-urinary organs (in Russian). Urol Nefrol 1982;2:25–28.
34.
Giacchetti S, Raoul Y, Wibault P, Droz JP, Court B, Eschwege F: Treatment of stage I testis seminoma by radiotherapy: Long-term results – a 30-year experience. Int J Radiat Oncol Biol Phys 1993;27:3–9.
35.
Hoff Wanderas E, Fossa SD, Tretli S: Risk of subsequent non-germ cell cancer after treatment of germ cell cancer in 2006 Norwegian male patients. Eur J Cancer 1997;33:253–262.
36.
Moller H, Mellemgaard A, Krag Jacobsen G, Pedersen D, Storm H: Incidence of second primary cancer following testicular cancer. Eur J Cancer 1993;29A5:672–676.
37.
Cahan WG, Woodard HQ, Higinbotham NL, Stewart FW, Coley BL: Sarcoma arising in irradiated bone: Report of 11 cases. Cancer 1948;1:3–29.
38.
Little JB: Cellular, molecular, and carcinogenic effects of radiation. Hematol Oncol Clin North Am 1993;7:337–352.
39.
Kaldor J: Second cancer following chemotherapy and radiotherapy. An epidemiological perspective. Acta Oncol 1990;29:647–655.
40.
Stein M, Loberant N, Iaviov M, Renner G, Lachter J, Kuten A: Second cancer in patients treated for testicular seminoma. J Surg Oncol 1992;49:16–19.
41.
Stone JM, Cruickshank DG, Sandeman TF, Matthews JP: Laterality, maldescent, trauma and other clinical factors in the epidemiology of testis cancer in Victoria, Australia. Br J Cancer 1991;64:132–138.
42.
Cavalli F, Fässler H, Kaplan S, Camponovo F: Testicular cancer after treatment for Hodgkin’s disease (letter). N Engl J Med 1980;302:1478–1479.
43.
Warde P, Gospodarowicz MK, Panzarella T, et al: Stage I testicular seminoma: Results of adjuvant irradiation and surveillance. J Clin Oncol 1995;13:2255–2262.
44.
Dieckmann KP, Loy V, Klan R: Seminoma testis and concomitant ipsilateral renal cell carcinoma. Urol Int 1988;43:49–52.
45.
Davis BE, Sogani PC, Herr HW: Association of primary germ cell tumor of the testis and renal cell carcinoma. J Urol 1993;150:1489–1491.
46.
Kleinerman RA, Lieberman JV: Li FP, Second cancer following cancer of the male genital system in Connecticut, 1935–82. Natl Cancer Inst Monogr 1985;68:139–147.
47.
Engelhard K, Sarmiento-Garcia G, Worlicek H: Renal space-occupying lesion of uncertain tumor status in metastatic testicular tumor. Röntgenblätter 1988;41:301–304.
48.
Nozawa M, Kishikawa H, Kojima Y, Seguchi T, Yoshioka T, Miki T, Okuyama A: Double cancers of renal cell carcinoma and testicular seminoma: A case report (in Japanese). Hinyokika Kiyo 1995;41:999–1002.
49.
Bayens YC, Helle PA, Van Putten WLJ, Mali SPM: Radiother Oncol 1992;25:97–102.
50.
Lioy Lupis MT, Quintana RM, Solano FM, Moro G, Romero CF: Asociación tumoral maligna del tracto genitourinario en un mismo paciento: Seminoma testicular, adenocarcinoma renal y adenocarcinoma prostata. Arch Esp Urol 1991;44:73–82.
51.
Khandekar JD, Neulist L, Dotson L: Renal carcinoma 30 years after abdominal irradiation for testicular seminoma. Lancet 1977;i:615.
52.
Horwich A, Bell J: Mortality and cancer incidence following radiotherapy for seminoma of the testis. Radiother Oncol 1994;30:193–198.
53.
Levinson AK, Johnson DE, Strong LC, Pathak S, Huff V, Saunders GF: Familial renal cell carcinoma: Hereditary or coincidental? J Urol 1990;144:849–851.
54.
Dexeus FH, Logothetis CJ, Kitboum R, Sella A, Chong C, Grignon D: Association of germ cell tumors and Hodgkin’s disease. Urology 1991;37:129–134.
55.
Robert M, Averous M, Lavabre-Bertrand T, et al: Cancer du testicule après maladie de Hodgkin. J Urol (Paris) 1992;98:178–180.
56.
Gerl A, Clemm C, Salat C, Mittermüller J, Bomfleur W, Wilmanns W: Testicular cancer and Hodgkin’s disease in the same patient. Cancer 1993;71:2838–2840.
57.
Kaldor JM, Day NE, Shiboski S: Epidemiological studies of anticancer drug carcinogenicity. IARC Sci Publ 1986;78:189–201.
58.
Hellbardt A, Mirimanoff RO, Obradovic M, Mermillod B, Paunier JD: The risk of second cancer (SC) in patients treated for testicular seminoma. Int J Radiat Oncol Biol Phys 1990;18:1327–1331.
59.
Glanzmann C, Schultz G, Lütolf UM: Long-term morbidity of adjuvant infradiaphragmatic irradiation in patients with testicular cancer and implications for the treatment of stage I seminoma. Radiother Oncol 1991;22:12–18.
60.
Coleman MP, Bell CMJ, Fraser P: Second primary malignancy after Hodgkin’s disease, ovarian cancer and cancer of the testis: A population-based cohort study. Br J Cancer 1987;56:349–355.
61.
Linassier C, Poumier-Gaschard P, Bremond J-L, et al: Simultaneous occurrence of acute myelogenous leukemia and seminoma of the testis. Cancer Chemother Pharmacol 1992;30:233–234.
62.
Musmano MC, White JM: Seminoma in an adult with acute lymphocytic leukemia. J Urol 1986;138:1083–1085.
63.
Akiyama Y, Kubota M, Mikawa H, Nakashima Y, Yamabe H: Embryonal carcinoma of the testis after acute myelomonocytic leukemia: A case report. Jpn J Clin Oncol 1991;21:59–61.
64.
Boshoff C, Begent RHJ, Oliver RTD, et al: Secondary tumours following etoposide containing therapy for germ cell cancer. Ann Oncol 1995;6:35–40.
65.
Pedersen-Bjergaard J, Daugaard G, Hansen SW, Philip P, Larsen SO, Rorth M: Increased risk of myelodysplasia and leukemia after etoposide, cisplatin, and bleomycin for germ-cell tumours. Lancet 1991;338:359–363.
66.
Bajorin DF, Motzer RJ, Rodriguez E, Murphy B, Bosl GJ: Acute nonlymphocytic leukemia in germ cell tumor patients treated with etoposide-containing chemotherapy. J Natl Cancer Inst 1993;85:60–62.
67.
Nichols CR, Breeden ES, Loehrer PJ, Williams SD, Einhorn LH: Secondary leukemia associated with a conventional dose of etoposide: Review of serial germ cell tumor protocols. J Natl Cancer Inst 1993;85:36–40.
68.
Bokemeyer C, Schmoll HJ: Secondary neoplasms following treatment of malignant germ cell tumors. J Clin Oncol 1993;11:1703–1709.
69.
Roth BJ, Einhorn LH, Greist A: Long-term complications of cis-platin-based chemotherapy for testis cancer. Semin Oncol 1988;15:345–350.
70.
Amichetti M, Felling G, Bolner A, et al: Stage I seminoma of the testis: Long term results and toxicity with adjuvant radiotherapy. Tumori 1994;80:141–145.
71.
Patton JF, Mallis N: Tumors of the testis. J Urol 1959;81:457–461.
72.
Krag Jacobsen G, Mellemgaard A, Engelholm SA, Moller H: Increased incidence of sarcoma in patients treated for testicular seminoma. Eur J Cancer 1993;29A:664–668.
73.
Katsohi D, Andreopolous M, Gofferje J, Karstens H: Neuere Aspekte zur adjuvanten Therapie des Stadium-I-Seminoms. Med Welt 1994;45:463–466.
© 2000 S. Karger AG, Basel
2000
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.